153 related articles for article (PubMed ID: 17415044)
1. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
Malet I; Wirden M; Derache A; Simon A; Katlama C; Calvez V; Marcelin AG
AIDS; 2007 Apr; 21(7):871-3. PubMed ID: 17415044
[TBL] [Abstract][Full Text] [Related]
2. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
Adamson CS; Ablan SD; Boeras I; Goila-Gaur R; Soheilian F; Nagashima K; Li F; Salzwedel K; Sakalian M; Wild CT; Freed EO
J Virol; 2006 Nov; 80(22):10957-71. PubMed ID: 16956950
[TBL] [Abstract][Full Text] [Related]
3. Determinants of activity of the HIV-1 maturation inhibitor PA-457.
Li F; Zoumplis D; Matallana C; Kilgore NR; Reddick M; Yunus AS; Adamson CS; Salzwedel K; Martin DE; Allaway GP; Freed EO; Wild CT
Virology; 2006 Dec 5-20; 356(1-2):217-24. PubMed ID: 16930665
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.
Verheyen J; Verhofstede C; Knops E; Vandekerckhove L; Fun A; Brunen D; Dauwe K; Wensing AM; Pfister H; Kaiser R; Nijhuis M
AIDS; 2010 Mar; 24(5):669-73. PubMed ID: 19926962
[TBL] [Abstract][Full Text] [Related]
5. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
Yebra G; Holguín A
Antivir Ther; 2008; 13(8):1083-5. PubMed ID: 19195334
[TBL] [Abstract][Full Text] [Related]
6. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
7. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
[TBL] [Abstract][Full Text] [Related]
8. [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
Kazennova EV; Vasil'ev AV; Bobkova MR
Vopr Virusol; 2010; 55(3):37-41. PubMed ID: 20608080
[TBL] [Abstract][Full Text] [Related]
9. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
Adekale MA; Cane PA; McCrae MA
J Med Virol; 2005 Feb; 75(2):195-201. PubMed ID: 15602725
[TBL] [Abstract][Full Text] [Related]
10. Insight into the mechanism of action of EP-39, a bevirimat derivative that inhibits HIV-1 maturation.
Neyret A; Gay B; Cransac A; Briant L; Coric P; Turcaud S; Laugâa P; Bouaziz S; Chazal N
Antiviral Res; 2019 Apr; 164():162-175. PubMed ID: 30825471
[TBL] [Abstract][Full Text] [Related]
11. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid.
Zhou J; Chen CH; Aiken C
Retrovirology; 2004 Jun; 1():15. PubMed ID: 15225375
[TBL] [Abstract][Full Text] [Related]
12. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
Adamson CS; Waki K; Ablan SD; Salzwedel K; Freed EO
J Virol; 2009 May; 83(10):4884-94. PubMed ID: 19279107
[TBL] [Abstract][Full Text] [Related]
13. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
14. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
Urano E; Timilsina U; Kaplan JA; Ablan S; Ghimire D; Pham P; Kuruppu N; Mandt R; Durell SR; Nitz TJ; Martin DE; Wild CT; Gaur R; Freed EO
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567982
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag.
Zhou J; Chen CH; Aiken C
J Virol; 2006 Dec; 80(24):12095-101. PubMed ID: 17035324
[TBL] [Abstract][Full Text] [Related]
16. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
DaFonseca S; Blommaert A; Coric P; Hong SS; Bouaziz S; Boulanger P
Antivir Ther; 2007; 12(8):1185-203. PubMed ID: 18240859
[TBL] [Abstract][Full Text] [Related]
17. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
[TBL] [Abstract][Full Text] [Related]
18. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
Yates PJ; Hazen R; St Clair M; Boone L; Tisdale M; Elston RC
Antimicrob Agents Chemother; 2006 Mar; 50(3):1092-5. PubMed ID: 16495277
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
Lin Z; Cantone J; Lu H; Nowicka-Sans B; Protack T; Yuan T; Yang H; Liu Z; Drexler D; Regueiro-Ren A; Meanwell NA; Cockett M; Krystal M; Lataillade M; Dicker IB
PLoS Pathog; 2016 Nov; 12(11):e1005990. PubMed ID: 27893830
[TBL] [Abstract][Full Text] [Related]
20. Primary drug resistance in antiretroviral-naïve injection drug users.
Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
